At a glance
ClinicalIndex Comparison RecordPhase 2Active· 16 target
Drug / intervention
Denosumab (Prolia) +1 moredrug
Likely dose
Denosumab (Prolia) 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Novel Treatment of Some Men With Non-Obstructive Azoospermia (NT-NOA): A Clinical Interventional Study
In Brief
A Phase 2 clinical trial evaluating Denosumab (Prolia) and Letrozole (Aromatase Inhibitors) for Infertility, Male. Active but no longer recruiting, targeting 16 participants across 1 site.
Detailed Summary
This clinical interventional study aims to assess whether treatment with denosumab in combination with letrozole can improve sperm production in infertile men with non-obstructive azoospermia selected by serum anti-mullerian hormone (AMH) as a positive predictive biomarker.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfertility, Male
CountriesDenmark
Collaborators--
Timeline
Phase 2Active
20252026
First PostedNov 2024
Enrollment StartMar 2025
TodayJul 2026
Primary CompletionAug 2026
First PostedNov 26, 2024
Enrollment StartMar 1, 2025
Primary CompletionAug 1, 2026
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 1.6 years agoPrimary completion in 29 days
Interventions
Denosumab (Prolia)drug
Subcutaneous injection with 60 mg Denosumab once
Letrozole (Aromatase Inhibitors)drug
Letrozole oral tablet 2.5 mg once daily